Godavari Biorefineries Ltd saw its shares soar nearly 10% following the announcement that its European patent application for “Compounds for the Inhibition of Unregulated Cell Growth” has been officially granted. This patent comes from the company’s Anti-Cancer Research Segment and represents a significant breakthrough in cancer research.
The newly patented compounds are designed to inhibit unregulated cell growth, with a special focus on targeting cancer stem cells. These compounds hold promising potential in treating various forms of cancer, including breast and prostate cancers.
The company stated that the patent covers detailed information on the chemical structures, synthesis methods, and biological activity of these innovative compounds. Early lab studies have shown encouraging results, demonstrating strong efficacy in slowing down cancer cell proliferation. These findings lay the groundwork for further pre-clinical and clinical evaluations.
Godavari Biorefineries shares showed strong intraday movement today, trading between a low of ₹238.10 and a high of ₹263.00. Over the past year, the share has seen a 52-week low of ₹145.00 and a high of ₹408.60.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
